A “team effort” for discovering how to diagnose and treat amyloidosis, a rare protein-folding disorder. Amyloidosis is a rare disorder that occurs when an abnormal amyloid protein deposits in organs and tissues, interfering with their ability to function normally. There are approximately 30 different types of amyloidosis, and the disease can either be systemic or (read more)
UT Graduate School of Medicine
From Discovery to Biopharmaceutical Startup: UTGSM Innovators Demonstrate Progress in Therapeutics for Systemic Amyloidosis
A team of researchers from the University of Tennessee Graduate School of Medicine has spent more than two decades investigating systemic amyloidosis, a rare and often fatal disorder with few treatments. Their work played an integral role in moving discoveries out of the lab and into clinical trials, helping launch a biopharmaceutical company focused on (read more)
UTRF Licensee Attralus Secures $25M in Investment
Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on (read more)